Physician profile
Peter W Komatz
NPI 1164442836
$1,132.23
in general payments reported to CMS, 2019-2025
15 companies · $787 in 2025
The $787 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $92.63 · 2024: $253 · 2025: $787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $940 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $939.65 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $291.27 | 2024-2025 | Xtandi, Vyloy |
| Astrazeneca Pharmaceuticals LP | $164.94 | 2025 | Datroway, Enhertu, Lynparza |
| Neurocrine Biosciences, INC. | $117.69 | 2024 | Ingrezza |
| Pfizer INC. | $110.38 | 2025 | |
| Janssen Pharmaceuticals, INC | $92.63 | 2022 | |
| Abbvie INC. | $73.36 | 2024-2025 | |
| Daiichi Sankyo INC. | $53.45 | 2025 | Datroway, Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $49.95 | 2024-2025 | Ninlaro |
| Genentech USA, INC. | $49.63 | 2024-2025 | Columvi, Venclexta |
| Ipsen Biopharmaceuticals, INC | $23.30 | 2025 | Onivyde |
| Glaxosmithkline, LLC. | $22.54 | 2024 | Jemperli, Zejula |
| Merck Sharp & Dohme LLC | $22.23 | 2025 | Keytruda, Lynparza |
| Kyowa Kirin, INC. | $21.06 | 2024 | Poteligeo |
| Janssen Biotech, INC. | $20.93 | 2025 | Rybrevant |
| Array Biopharma INC | $18.87 | 2025 | Braftovi, Mektovi, Tukysa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Komatz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.